Nathan S. Kline Institute for Psychiatric Research
🇺🇸United States
Clinical Trials
22
Active:0
Completed:18
Trial Phases
3 Phases
Phase 2:8
Phase 4:7
Not Applicable:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Phase 2
8 (36.4%)Not Applicable
7 (31.8%)Phase 4
7 (31.8%)Sodium Butyrate For Improving Cognitive Function In Schizophrenia
Phase 2
Withdrawn
- Conditions
- Schizophrenic DisordersCognitive Function
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Registration Number
- NCT02654405
- Locations
- 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg,, New York, United States
D-serine and Cognitive Remediation in Schizophrenia
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 8
- Registration Number
- NCT02156908
- Locations
- 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
Not Applicable
Completed
- Conditions
- CognitionCigarette SmokingSchizophrenia
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 33
- Registration Number
- NCT02128919
- Locations
- 🇺🇸
Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
Phase 2
- Conditions
- Schizoaffective DisorderSchizophrenia
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 16
- Registration Number
- NCT01474395
- Locations
- 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States
Conversion to Antipsychotic Monotherapy
Not Applicable
Terminated
- Conditions
- Schizoaffective DisorderSchizophrenia
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 24
- Registration Number
- NCT01368458
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found